IMM is positioning itself as a leader in next generation Autoimmune Disease Treatments9 Sep 2025 19:31
The new patent filing provides 20 years of commercial exclusivity for both the diagnostic test and P140 therapy, positioning ImmuPharma as a leader in the next generation of autoimmune disease treatments.
Market Opportunity:
Autoimmune diseases affect more than 400 million people worldwide, with a therapeutic market valued at over $100 billion annually. Current treatments remain limited and often unsafe, highlighting a major unmet medical need.
In parallel, the autoimmune diagnostics market represents a rapidly growing opportunity, valued at over $10 billion globally, as healthcare systems increasingly adopt precision diagnostics.
ImmuPharma's novel diagnostic test, designed to identify patients with Type M immune disorder, not only strengthens the value proposition of P140 but also creates an independent commercial opportunity with potential for earlier adoption and partnerships.
With this dual platform - first-in-class therapy plus precision diagnostic - ImmuPharma is pioneering a new era of precision medicine in autoimmune disease, offering accurate diagnosis and a groundbreaking treatment with the potential to achieve full remission.
Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said:
"The new patent on P140 is the result of impressive and dedicated research by ImmuPharma Biotech and is truly a game changer for ImmuPharma. The discovery of a new mechanism of action and identification of Type M, a sub-type of auto-immune disorders, greatly expands the scope ofP140 across a wide range of autoimmune diseases and the filing of a patent application directed towards this discovery significantly enhances the business case due to the potential for long-term increased revenues.
This combination makes P140 a unique and extremely valuable asset, particularly with the potential for 20 years of commercial exclusivity, and will add enormous traction to our current discussions with potential global partners of P140."
Sign In
Follow the stocks
